MigraineMind research summary
Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea.
Drugs Real World Outcomes | 2026
Observational studySummary
Fremanezumab is being evaluated for its safety and effectiveness in South Korea. This study focuses on adults with migraines using fremanezumab for the first time. It is a 6-year, non-interventional study across 60 clinics and hospitals. The primary goal is to track new adverse events within 12 weeks. Secondary goals include changes in average monthly migraine days and participant satisfaction. The interim analysis includes data from 14 sites with 1230 participants for safety analysis. Among these, 17.6% reported adverse events, mainly injection-site reactions at 5.7%. Serious adverse events occurred in 1.0% of participants. After 12 weeks, average monthly migraine days decreased by 7.8 days. About 56% of participants achieved a greater than 50% reduction in migraine days. Most participants, 87%, found the treatment effective. These findings support fremanezumab's use in real-world settings in South Korea. Clinical relevance: This research shows fremanezumab effectively reduces migraines in real-world clinical practice, benefiting patients and guiding treatment decisions for clinicians.
Key Learning Points
- Fremanezumab is being studied for its safety and effectiveness in treating migraines among adults in South Korea.
- In the study, 17.6% of participants reported adverse events, primarily related to injection sites.
- After 12 weeks of treatment, participants experienced an average reduction of 7.8 migraine days per month.
- More than half of the participants, 56%, achieved a significant reduction in their migraine days.
- A large majority, 87%, of participants found fremanezumab to be an effective treatment for their migraines.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.